3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
3
Hematologic Neoplasms
2
Teratoma
1
Stroke
1
Pulmonary Disease, Chronic Obstructive
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Kidney Failure, Chronic
1
Hepatitis B
1
Hematopoietic and Lymphatic System Neoplasm
1
Endometrial Clear Cell Adenocarcinoma
1
Endodermal Sinus Tumor
1
Diabetes Mellitus
1
Coronary Artery Disease
1
Colonic Neoplasms
1
Carcinoma, Embryonal
1
COVID-19
1
Breast Neoplasms
1
Anatomic Stage I Breast Cancer AJCC v8
1
Interventions
Fluorouracil
72
Leucovorin
71
Oxaliplatin
47
Irinotecan
31
Capecitabine
24
Bevacizumab
23
Folfox protocol
20
Cetuximab
15
Chemotherapy, Adjuvant
13
Celecoxib
7
Aspirin
6
Laparoscopy
5
XELOX
4
Panitumumab
4
Neoadjuvant Therapy
4
Levamisole
4
dehydroftorafur
3
Tegafur
3
Surgical Procedures, Operative
3
Observation
3
Floxuridine
3
vatalanib
2
tislelizumab
2
pertuzumab
2
encorafenib
2
atezolizumab
2
Trastuzumab
2
Standard of Care
2
Semaxinib
2
Selenium
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Colonic Neoplasms
×
Practice Guidelines as Topic
×
Clear all
NCT06563388
2026-02-04
ID-COMET
Roswell Park Cancer Institute
Phase 3
Recruiting
800 enrolled